close
MENU
How to guide
How to guide
Home
The NBR List
NBR View
NBR Marketplace

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

Podcasts Audio Articles Entrepreneurs Your Business Beehive Banter Morning Brew Toil & Trouble NZ Aviation News Back Issues Market Outlook Dollars & Sense Private Bin Opinion (Archive) NBR Radar (Archive) NBR Rich List (Archive)
Investment
5 mins to read
3

Douglas Pharmaceuticals launches into $100m investment programme

New marketing subsidiary established in the US.

Graham Skellern Tue, 23 Apr 2019

Auckland-based Douglas Pharmaceuticals has begun construction of a new $35 million research and development (R&D) facility as the family-owned business continues a strong growth phase.

The company, established by pharmacist Graeme Douglas in 1967, is fast running out of space for its growing

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Graham Skellern Tue, 23 Apr 2019
Contact the Writer: graham@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
Douglas Pharmaceuticals Jeff Douglas medicines US FDA Investment
Related News
General Business

Douglas Pharmaceuticals, Rockit Global join PCNZ to boost China business

Douglas Pharma aims to double revenue by 2025
1

NZ's only drug giant, Douglas Pharmaceuticals, to stay in the family
Related News
General Business

Douglas Pharmaceuticals, Rockit Global join PCNZ to boost China business

Douglas Pharma aims to double revenue by 2025
1

NZ's only drug giant, Douglas Pharmaceuticals, to stay in the family
Douglas Pharmaceuticals launches into $100m investment programme
Investment,General Business,
78973
true
Subscribe Login